慢性阻塞性肺疾病治疗最新研究进展  

Research progress of new treatments for chronic obstructive pulmonary disease

作　　者：段丽娜[1] 王贵佐[2] 

机构地区：[1]陕西省韩城市人民医院内二科,715400 [2]陕西省人民医院呼吸科

出　　处：《中华临床医师杂志（电子版）》2014年第24期118-121,共4页Chinese Journal of Clinicians(Electronic Edition)

摘　　要：慢性阻塞性肺疾病(COPD)是全球重要的健康问题。其特点为慢性炎症,进而导致进行性发展的、不完全可逆的气流受限。目前的治疗措施主要为控制慢性炎症,然而目前的抗炎疗法不能抑制疾病的进展。因此多个研究开始致力于寻找炎症关键调节蛋白并进行靶向治疗,如CXCR2拮抗剂可有效抑制中性粒细胞性炎症,PDE-4、p38MAPK、JAK-STAT和IL-6抑制剂同样对COPD具有潜在的治疗作用,本文就上述药物对COPD的保护作用做一综述,以期为COPD的临床治疗提供新的理论依据。Chronic obstructive pulmonary disease（COPD） is a major health problem worldwide. It is characterized by chronic inflammation in the lungs that leads to progressive chronic airflow obstruction. The main strategy for treating COPD is control of the chronic inflammation. However, current antiinflammatory treatments fail to prevent disease progression. Research has been focused on identifying the key inflammatory regulators. CXCR2 antagonists inhibit neutrophilic inflammation, inhibitors of phosphodiesterase-4（PDE4）, p38 mitogen-activated protein kinase（p38 MAPK）, Janus kinases and IL-6 have also shown some promising effects. This review summarized recent studies of protective functions of the drugs described above in COPD, in order to provide the oretical basis for clinical treatment of COPD.

关 键 词：磷酸二酯酶抑制剂 肺疾病 慢性阻塞性 细胞因子抑制剂 趋化因子抑制剂 磷酸肌醇3激酶抑制剂 

分 类 号：R563.9[医药卫生—呼吸系统]